News | 25 August 2025
GSK forays into oncology in India with Jemperli and Zejula
The company is bringing precision therapies for gynaecological cancers
The company is bringing precision therapies for gynaecological cancers
Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040
This project shall be implemented through incorporation of a new joint venture company in Zambia
The company has improved access to quality healthcare for seniors across both urban and rural areas
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
Inclacumab was generally well tolerated in THRIVE-131
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
The projected business potential is around US$ 1 million in the first year
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Subscribe To Our Newsletter & Stay Updated
